Effect of hepatitis C virus on immunological and virological responses in HIV-infected patients initiating highly active antiretroviral therapy: A meta-analysis

Journal of Viral Hepatitis

Volumn 20, Issue 10, 2013, Pages 715-724

  Tsiara, C G ^a   Nikolopoulos, G K ^a,b   Dimou, N L ^c   Bagos, P G ^c   Saroglou, G ^d   Velonakis, E ^d   Hatzakis, A ^e  

^a Hellenic Centre for Disease Control and Prevention   (Greece)

^b NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES   (United States)

^c UNIVERSITY OF CENTRAL GREECE   (Greece)

^d UNIVERSITY OF ATHENS   (Greece)

^e UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

antiretroviral treatment; HCV; HIV; immunological response; virological response

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; CD4 LYMPHOCYTE COUNT; DATA BASE; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; VIROLOGY;

ANTIRETROVIRAL TREATMENT; HCV; HIV; IMMUNOLOGICAL RESPONSE; VIROLOGICAL RESPONSE;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; HEPATITIS C; HIV; HIV INFECTIONS; HUMANS; VIRAL LOAD;

EID: 84884127090     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12101     Document Type: Article

References (63)

1. UNAIDS. Global report: UNAIDS report on the global AIDS epidemic 2010. Available at: http://www.unaids.org/globalreport/global-report.htm (accessed 3 September 2012).
2. Puhan MA, Van Natta ML, Palella FJ, Addessi A, Meinert C, Ocular Complications of AIDS Research Group. Excess mortality in patients with AIDS in the era of highly active antiretroviral therapy: temporal changes and risk factors. Clin Infect Dis 2010; 51: 947-956.
3. Soriano V, Vispo E, Labarga P, Medrano J, Barreiro P,. Viral hepatitis and HIV co-infection. Antiviral Res 2010; 85: 303-315.
4. Nelson PK, Mathers BM, Cowie B, et al,. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011; 378: 571-583.
5. Larsen C, Pialoux G, Salmon D, et al,. Prevalence of hepatitis C and hepatitis B infection in the HIV-infected population of France, 2004. Euro Surveill 2008; 13: 1-4.pii=18888. Available at: http://www.eurosurveillance.org/ ViewArticle.aspx?ArticleId=18888 (accessed 3 September 2012).
6. Mohsen AH, Murad S, Easterbrook PJ,. Prevalence of hepatitis C in an ethnically diverse HIV-1-infected cohort in south London. HIV Med 2005; 6: 206-215.
7. Solomon SS, Srikrishnan AK, Mehta SH, et al,. High prevalence of HIV, HIV/hepatitis C virus co-infection, and risk behaviors among injection drug users in Chennai, India: a cause for concern. J Acquir Immune Defic Syndr 2008; 49: 327-332.
8. Danta M, Rodger AJ,. Transmission of HCV in HIV-positive populations. Curr Opin HIV AIDS 2011; 6: 451-458.
9. Greub G, Ledergerber B, Battegay M, et al,. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus co-infection: the Swiss HIV Cohort Study. Lancet 2000; 356: 1800-1805.
10. Anderson KB, Guest JL, Rimland D,. Hepatitis C virus co-infection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study. Clin Infect Dis 2004; 39: 1507-1513.
11. Macías J, Pineda JA, Leal M, et al,. Influence of hepatitis C virus infection on the mortality of antiretroviral-treated patients with HIV disease. Eur J Clin Microbiol Infect Dis 1998; 17: 167-170.
12. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL,. Hepatitis C and progression of HIV disease. JAMA 2002; 288: 199-206.
13. Chen TY, Ding EL, Seage GR III, Kim AY,. Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis 2009; 49: 1605-1615.
14. Miller MF, Haley C, Koziel MJ, Rowley CF,. Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis. Clin Infect Dis 2005; 41: 713-720.
15. Stroup DF, Berlin JA, Morton SC, et al,. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 2000; 283: 2008-2012.
16. Moher D, Liberati A, Tetzlaff J, Altman DG,. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010; 8: 336-341.
17. Petitti DB,. Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis, 2nd ed. New York: Oxford University Press, 2000.
18. DerSimonian R, Laird N,. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
19. Perneger T,. Estimating the relative hazard by the ratio of logarithms of event-free proportions. Contemp Clin Trials 2008; 29: 762-766.
20. Higgins JP, Thompson SG, Deeks JJ, Altman DG,. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
21. Begg CB, Mazumdar M,. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101.
22. Egger M, Davey Smith G, Schneider M, Minder C,. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
23. Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC,. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 1992; 327: 248-254.
24. Riley RD, Thompson JR, Abrams KR,. An alternative model for bivariate random-effects meta-analysis when the within-study correlations are unknown. Biostatistics 2008; 9: 172-186.
25. Santin M, Mestre M, Shaw E, et al,. Impact of hepatitis C virus co-infection on immune restoration during successful antiretroviral therapy in chronic human immunodeficiency virus type 1 disease. Eur J Clin Microbiol Infect Dis 2008; 27: 65-73.
26. Braitstein P, Zala C, Yip B, et al,. Immunologic response to antiretroviral therapy in hepatitis C virus-co-infected adults in a population-based HIV/AIDS treatment program. J Infect Dis 2006; 193: 259-268.
27. Antonucci G, Girardi E, Cozzi-Lepri A, et al,. HepaI.Co.N.A. Study Group, Italian Cohort Naive for Antiretrovirals Study Group. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naïve HIV-infected individuals. Clin Infect Dis 2005; 40: e101-e109.
28. Castagna A, Galli L, Torti C, et al,. Predicting the magnitude of short-term CD4 (+) T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy. Antivir Ther 2010; 15: 165-175.
29. Seminari E, Tinelli C, Ravasi G, et al,. MASTER Cohort. Hepatitis C infection on immune recovery in HIV-positive patients on successful HAART: the role of genotype 3. Curr HIV Res 2010; 8: 186-193.
30. lsa SE, Gwamzhi LN, Akolo C, Giyan J,. A prospective cohort study of immunologic and virologic outcomes in patients with HIV/AIDS and hepatitis virus co-infection in Jos, Nigeria. Niger J Med 2010; 19: 279-285.
31. Emokpae MA, Nwokedi EE, Jegede EE,. Impact of hepatitis C co-infection on CD4 T cell count in HIV infected subjects. OJHAS 2008; 7: 1-4.
32. Macías J, Pineda JA, Lozano F, et al,. Impaired recovery of CD4 + cell counts following highly active antiretroviral therapy in drug-naïve patients coinfected with human immunodeficiency virus and hepatitis C virus. Eur J Clin Microbiol Infect Dis 2003; 22: 675-680.
33. Rockstroh JK, Mocroft A, Soriano V,. et al. EuroSIDA Study Group. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192: 992-1002.
34. De Luca A, Bugarini R, Lepri AC, et al,. Italian Cohort Naive Antiretrovirals Study Group. Co-infection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med 2002; 162: 2125-2132.
35. Klein MB, Lalonde RG, Suissa S,. The impact of hepatitis C virus co-infection on HIV progression before and after highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2003; 33: 365-372.
36. Chung RT, Evans SR, Yang Y, et al,. AIDS Clinical Trials Group 383 Study Team. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS 2002; 16: 1915-1923.
37. Zhou J, Dore GJ, Zhang F, Lim PL, Chen YM, TREAT Asia HIV Observational Database. Hepatitis B and C virus co-infection in The TREAT Asia HIV Observational Database. J Gastroenterol Hepatol 2007; 22: 1510-1518.
38. Carmo RA, Guimarães MD, Moura AS, et al,. The influence of HCV co-infection on clinical, immunological and virological responses to HAART in HIV-patients. Braz J Infect Dis 2008; 12: 173-179.
39. Turner J, Bansi L, Gilson R, et al,. UK Collaborative HIV Cohort (UK CHIC) Study. The prevalence of hepatitis C virus (HCV) infection in HIV-positive individuals in the UK-trends in HCV testing and the impact of HCV on HIV treatment outcomes. J Viral Hepat 2010; 17: 569-577.
40. Stapleton JT, Bennett K, Bosch RJ, Polgreen PM, Swindells S,. Effect of antiretroviral therapy and hepatitis C co-infection on changes in lipid levels in HIV-Infected patients 48 weeks after initiation of therapy. HIV Clin Trials 2007; 8: 429-436.
41. Lincoln D, Petoumenos K, Dore GJ, Australian HIV Observational Database. HIV/HBV and HIV/HCV co-infection, and outcomes following highly active antiretroviral therapy. HIV Med 2003; 4: 241-249.
42. Filippini P, Coppola N, Scolastico C, et al,. Can HCV affect the efficacy of anti-HIV treatment? Arch Virol 2000; 145: 937-944.
43. Zhao J, Yu ZJ, Kan QC, Li XF, Li ZQ, Liang HX,. A retrospective study: the influence of human immunodeficiency virus co-infection with hepatitis C virus or hepatitis B virus on the efficacy with HAART in China AIDS area. Life Science J 2011; 8: 27-31.
44. Thein HH, Yi Q, Dore GJ, Krahn MD,. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008; 22: 1979-1991.
45. Martin-Carbonero L, de Ledinghen V, Moreno A, et al,. Liver fibrosis in patients with chronic hepatitis C and persistently normal liver enzymes: influence of HIV infection. J Viral Hepat 2009; 16: 790-795.
46. Smit C, van den Berg C, Geskus R, Berkhout B, Coutinho R, Prins M,. Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-co-infected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study. J Acquir Immune Defic Syndr 2008; 47: 221-225.
47. Operskalski EA, Kovacs A,. HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr HIV/AIDS Rep 2011; 8: 12-22.
48. Laskus T, Radkowski M, Jablonska J, et al,. Human immunodeficiency virus facilitates infection/replication of hepatitis C virus in native human macrophages. Blood 2004; 103: 3854-3859.
49. Hunt PW, Martin JN, Sinclair E, et al,. T cell activation is associated with lower CD4 T+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187: 1534-1543.
50. Sandberg JK, Falconer K, Gonzalez VD,. Chronic immune activation in the T cell compartment of HCV/HIV-1 co-infected patients. Virulence 2010; 1: 177-179.
51. Gonzalez VD, Falconer K, Blom KG, et al,. High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment. J Virol 2009; 83: 11407-11411.
52. Korner C, Kramer B, Schulte D, et al,. Effects of HCV co-infection on apoptosis of CD4 T-cells in HIV positive patients. Clin Sci 2009; 116: 861-870.
53. Pulido F, Hill A, van Delft Y, Moecklinghoff C,. Impact of hepatitis C co-infection on response to antiretroviral treatment. AIDS Rev 2012; 14: 124-131.
54. Horberg M, Silverberg M, Hurley L, Delorenze G, Quesenberry C,. Influence of prior antiretroviral experience on adherence and responses to new highly active antiretroviral therapy regimens. AIDS Patient Care STDS 2008; 22: 301-312.
55. Thomas DL, Astemborski J, Rai RM, et al,. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284: 450-456.
56. European AIDS Clinical Society. European Guidelines for treatment of HIV infected adults in Europe-Version 6. Available at: http://www. europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/EACSGuidelines-v6. 0-English.pdf (accessed 3 September 2012).
57. Collazos J, Asensi V, Carton JA, Grupo Español para el Estudio Multifactorial de la Adherencia (GEEMA). Association of HIV transmission categories with sociodemographic, viroimmunological and clinical parameters of HIV-infected patients. Epidemiol Infect 2010; 138: 1016-1024.
58. Mocroft A, Madge S, Johnson AM, et al,. A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. J Acquir Immune Defic Syndr 1999; 22: 369-378.
59. Wisaksana R, Indrati AK, Fibriani A, et al,. Response to first-line antiretroviral treatment among human immunodeficiency virus-infected patients with and without a history of injecting drug use in Indonesia. Addiction 2010; 105: 1055-1061.
60. Mehta SH, Lucas G, Astemborski J, Kirk GD, Vlahov D, Galai N,. Early immunologic and virologic responses to highly active antiretroviral therapy and subsequent disease progression among HIV-infected injection drug users. AIDS Care 2007; 19: 637-645.
61. Giordano TP, Hartman C, Gifford AL, Backus LI, Morgan RO,. Predictors of retention in HIV care among a national cohort of US veterans. HIV Clin Trials 2009; 10: 299-305.
62. Ortego C, Huedo-Medina TB, Llorca J, et al,. Adherence to highly active antiretroviral therapy (HAART): a meta-analysis. AIDS Behav 2011; 15: 1381-1396.
63. Malta M, Strathdee SA, Magnanini MM, Bastos FI,. Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review. Addiction 2008; 103: 1242-1257.